Pfizer, Inc. (PFE) Shares Sold by Camelot Portfolios LLC

Camelot Portfolios LLC trimmed its position in shares of Pfizer, Inc. (NYSE:PFE) by 53.5% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 7,468 shares of the biopharmaceutical company’s stock after selling 8,597 shares during the quarter. Camelot Portfolios LLC’s holdings in Pfizer were worth $251,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently modified their holdings of the company. Boston Partners grew its stake in shares of Pfizer by 7.3% during the first quarter. Boston Partners now owns 24,263,989 shares of the biopharmaceutical company’s stock valued at $830,071,000 after purchasing an additional 1,649,801 shares during the last quarter. Sanders Capital LLC grew its stake in shares of Pfizer by 10.8% during the second quarter. Sanders Capital LLC now owns 16,933,077 shares of the biopharmaceutical company’s stock valued at $626,222,000 after purchasing an additional 1,644,036 shares during the last quarter. Bank of Nova Scotia grew its stake in shares of Pfizer by 325.9% during the first quarter. Bank of Nova Scotia now owns 1,934,514 shares of the biopharmaceutical company’s stock valued at $66,180,000 after purchasing an additional 1,480,258 shares during the last quarter. Fisher Asset Management LLC grew its stake in shares of Pfizer by 3.9% during the second quarter. Fisher Asset Management LLC now owns 34,035,362 shares of the biopharmaceutical company’s stock valued at $1,143,248,000 after purchasing an additional 1,275,832 shares during the last quarter. Finally, Longview Partners Guernsey LTD grew its stake in shares of Pfizer by 6.9% during the second quarter. Longview Partners Guernsey LTD now owns 18,468,572 shares of the biopharmaceutical company’s stock valued at $620,359,000 after purchasing an additional 1,189,059 shares during the last quarter. 69.01% of the stock is currently owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally posted by Community Financial News and is the property of of Community Financial News. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of US and international trademark and copyright legislation. The correct version of this piece of content can be read at https://www.com-unik.info/2017/11/03/pfizer-inc-pfe-shares-sold-by-camelot-portfolios-llc.html.

Several research firms have recently commented on PFE. Berenberg Bank set a $36.00 price target on shares of Pfizer and gave the company a “neutral” rating in a research note on Tuesday. Jefferies Group LLC set a $39.00 price target on shares of Pfizer and gave the company a “neutral” rating in a research note on Thursday, October 26th. BMO Capital Markets set a $39.00 price target on shares of Pfizer and gave the company a “buy” rating in a research note on Tuesday. UBS AG set a $38.00 price target on shares of Pfizer and gave the company a “buy” rating in a research note on Wednesday. Finally, Goldman Sachs Group, Inc. (The) set a $36.00 price target on shares of Pfizer and gave the company a “neutral” rating in a research note on Wednesday. Two research analysts have rated the stock with a sell rating, eight have assigned a hold rating and thirteen have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus price target of $38.35.

In other news, insider Alexander R. Mackenzie sold 15,000 shares of the business’s stock in a transaction that occurred on Monday, August 7th. The shares were sold at an average price of $33.50, for a total value of $502,500.00. Following the transaction, the insider now owns 151,474 shares in the company, valued at approximately $5,074,379. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Sally Susman sold 38,230 shares of the business’s stock in a transaction that occurred on Tuesday, September 12th. The stock was sold at an average price of $35.00, for a total transaction of $1,338,050.00. Following the completion of the transaction, the insider now owns 145,649 shares in the company, valued at approximately $5,097,715. The disclosure for this sale can be found here. Insiders sold a total of 389,621 shares of company stock worth $13,298,598 in the last 90 days. Corporate insiders own 0.06% of the company’s stock.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.67 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.65 by $0.02. The firm had revenue of $13.17 billion for the quarter, compared to the consensus estimate of $13.17 billion. Pfizer had a net margin of 18.69% and a return on equity of 25.67%. The company’s revenue for the quarter was up .9% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.61 EPS.

The company also recently declared a quarterly dividend, which will be paid on Friday, December 1st. Stockholders of record on Friday, November 10th will be given a $0.32 dividend. The ex-dividend date is Thursday, November 9th. This represents a $1.28 dividend on an annualized basis and a dividend yield of 3.61%. Pfizer’s dividend payout ratio (DPR) is currently 79.01%.

Pfizer Profile

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer, Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

What are top analysts saying about Pfizer Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Pfizer Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit